|
FDA panel votes against dapagliflozin, casting doubt over the drug class of SGLT2 inhibitors. |
 |
|
Forbes: Goldman Sachs pharmaceuticals analyst Jami Rubin said in a note to investors that the rejection of dapagliflozin, a new diabetes drug from Bristol-Myers Squibb and AstraZeneca, by a panel of advisers to the Food and Drug Administration probably means that safety and efficacy concerns will either limit the use of similar new medicines, known as SGLT2 inhibitors, or prevent them from being approved entirely.
|